Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Chemotherapy Followed by Radiotherapy in the Perioperative Treatment of Gastroesophageal Junction Adenocarcinoma
NCT06163729Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2022
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastroesophageal junction adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06163729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06163729.